{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:17:08Z","timestamp":1778944628755,"version":"3.51.4"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC3602900"],"award-info":[{"award-number":["2022YFC3602900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81974099"],"award-info":[{"award-number":["81974099"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170785"],"award-info":[{"award-number":["82170785"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372831,82403963"],"award-info":[{"award-number":["82372831,82403963"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004912","name":"Sichuan University","doi-asserted-by":"publisher","award":["2020HXFH033"],"award-info":[{"award-number":["2020HXFH033"]}],"id":[{"id":"10.13039\/501100004912","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ctrv.2025.102935","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T12:00:12Z","timestamp":1744200012000},"page":"102935","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Operationalizing intermediate clinical endpoints: A pragmatic framework for prostate cancer management trials"],"prefix":"10.1016","volume":"136","author":[{"given":"Xingyu","family":"Xiong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiajia","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyang","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weitao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2025.102935_b0005","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrc702","article-title":"The promise and peril of surrogate end points in cancer research","volume":"2","author":"Schatzkin","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2025.102935_b0010","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1200\/JCO.22.00535","article-title":"Overall survival, progression-free survival, and tumor response benefit supporting initial US Food and Drug Administration approval and indication extension of new cancer drugs, 2003-2021","volume":"40","author":"Michaeli","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102935_b0015","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1001\/jamainternmed.2018.8351","article-title":"Estimation of study time reduction using surrogate end points rather than overall survival in oncology clinical trials","volume":"179","author":"Chen","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ctrv.2025.102935_b0020","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1001\/jamainternmed.2020.1097","article-title":"FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019","volume":"180","author":"Chen","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ctrv.2025.102935_b0025","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/jamainternmed.2015.2829","article-title":"The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses","volume":"175","author":"Prasad","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ctrv.2025.102935_b0030","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1001\/jamainternmed.2018.4710","article-title":"Evaluating progression-free survival as a surrogate outcome for health-related quality of life in oncology: a systematic review and quantitative analysis","volume":"178","author":"Kovic","year":"2018","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ctrv.2025.102935_b0035","first-page":"00152","article-title":"Overall survival benefits of cancer drugs initially approved by the US Food and Drug Administration on the basis of immature survival data: a retrospective analysis","volume":"S1470\u20132045","author":"Naci","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.102935_b0040","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1200\/JCO.2017.73.9987","article-title":"Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer","volume":"35","author":"Xie","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102935_b0045","article-title":"The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP)","volume":"107","author":"Sweeney","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2025.102935_b0050","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.annonc.2023.11.017","article-title":"Validation of metastasis-free survival as a surrogate endpoint for overallsurvival in localized prostate cancer in the era of docetaxel forcastration-resistant prostate cancer","volume":"35","author":"Xie","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2025.102935_b0145","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ctrv.2025.102935_b0135","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkz002","article-title":"A Systematic Review and Recommendation for Reporting of Surrogate Endpoint Evaluation Using Meta-analyses","volume":"3","author":"Xie","year":"2019","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.ctrv.2025.102935_b0080","doi-asserted-by":"crossref","unstructured":"Buyse M, Molenberghs G. Criteria for the validation of surrogate endpoints in randomized experiments. Biometrics.1998;54:1014-29.","DOI":"10.2307\/2533853"},{"key":"10.1016\/j.ctrv.2025.102935_b0085","doi-asserted-by":"crossref","unstructured":"Buyse M, Molenberghs G, Burzykowski T, et al. The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics.2000;1:49-67.","DOI":"10.1093\/biostatistics\/1.1.49"},{"key":"10.1016\/j.ctrv.2025.102935_b0090","article-title":"Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis","volume":"375","author":"Conforti","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ctrv.2025.102935_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2024.04.024","article-title":"Challenges and Opportunities in Establishing Appropriate Intermediate Endpoints Reflecting Patient Benefit: A Roadmap for Research and Clinical Application in Nonmetastatic Prostate Cancer","author":"Brookman-May","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2025.102935_b0100","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/sim.4780080407","article-title":"Surrogate endpoints in clinical trials: definition and operational criteria","volume":"8","author":"Prentice","year":"1989","journal-title":"Stat Med"},{"key":"10.1016\/j.ctrv.2025.102935_b0105","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/(SICI)1097-0258(19970715)16:13<1515::AID-SIM572>3.0.CO;2-1","article-title":"Estimating the proportion of treatment effect explained by a surrogate marker","volume":"16","author":"Lin","year":"1997","journal-title":"Stat Med"},{"key":"10.1016\/j.ctrv.2025.102935_b0110","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S1470-2045(08)70236-5","article-title":"Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial","volume":"9","author":"Denham","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.102935_b0115","doi-asserted-by":"crossref","first-page":"605","DOI":"10.7326\/0003-4819-125-7-199610010-00011","article-title":"Surrogate end points in clinical trials: are we being misled?","volume":"125","author":"Fleming","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ctrv.2025.102935_b0120","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/S1470-2045(24)00015-9","article-title":"Considerations for using potential surrogate endpoints in cancer screening trials","volume":"25","author":"Webb","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.102935_b0125","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/jnci\/djs527","article-title":"Surrogate endpoint analysis: an exercise in extrapolation","volume":"105","author":"Baker","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2025.102935_b0130","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/pst.207","article-title":"Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation","volume":"5","author":"Burzykowski","year":"2006","journal-title":"Pharm Stat"},{"key":"10.1016\/j.ctrv.2025.102935_b0140","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s10147-009-0885-4","article-title":"Meta-analysis for the evaluation of surrogate endpoints incancer clinical trials","volume":"14","author":"Shi","year":"2009","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102935_b0150","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.ctrv.2025.102935_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102156","article-title":"Intermediate endpoints as surrogates for outcomes in cancer immunotherapy: a systematic review and meta-analysis of phase 3 trials","volume":"63","author":"Zhang","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ctrv.2025.102935_b0070","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.1029","article-title":"Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis","volume":"3","author":"Blumenthal","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2025.102935_b0075","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1002\/ijc.31995","article-title":"Progression-free survival and one-year milestone survival as surrogates for overall survival in previously treated advanced non-small cell lung cancer","volume":"144","author":"Zhao","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2025.102935_b0155","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1017\/S0266462314000300","article-title":"Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers","volume":"30","author":"Ciani","year":"2014","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.ctrv.2025.102935_b0160","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/bimj.201400049","article-title":"Statistical evaluation of surrogate endpoints with examples from cancer clinical trials","volume":"58","author":"Buyse","year":"2016","journal-title":"Biom J"},{"key":"10.1016\/j.ctrv.2025.102935_b0165","unstructured":"Institute for Quality and Efficiency in Health Care. Validity of surrogate endpoints in oncology: executive summary of rapid report A10-05, version 1.1. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG), 2011 (https:\/\/www.iqwig.de\/en\/projects\/a10-05.html)."},{"key":"10.1016\/j.ctrv.2025.102935_b0170","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1470-2045(20)30730-0","article-title":"Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis","volume":"22","author":"Gharzai","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2025.102935_b0175","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200195","article-title":"Meta-analysis of candidate surrogate end points in advanced prostate cancer","volume":"2","author":"Gharzai","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.ctrv.2025.102935_b0180","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1200\/JCO.19.03114","article-title":"Event-free survival, a prostatespecific antigen\u2013based composite end point, is not a surrogate for overall survival in men with localized prostate cancer treated with radiation","volume":"38","author":"Xie","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102935_b0185","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1200\/JCO.21.02741","article-title":"Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology\/RTOG 9601","volume":"40","author":"Jackson","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102935_b0190","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1200\/JCO.18.00154","article-title":"Time Interval to Biochemical Failure as a Surrogate End Point in Locally Advanced Prostate Cancer: Analysis of Randomized Trial NRG\/RTOG 9202","volume":"37","author":"Dignam","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102935_b0200","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1200\/JCO.19.03114","article-title":"Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation","volume":"38","author":"Xie","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102935_b0205","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1200\/JCO.23.00617","article-title":"Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate","volume":"41","author":"Roy","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102935_b0210","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41391-020-0231-5","article-title":"Surrogate endpoints for overall survival for patients with metastatic hormone-sensitive prostate cancer in the CHAARTED trial","volume":"23","author":"Martini","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ctrv.2025.102935_b0215","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1002\/cncr.30587","article-title":"Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel","volume":"123","author":"Armstrong","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2025.102935_b0220","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1158\/1078-0432.CCR-14-1549","article-title":"Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate-Treated Castration-Resistant Prostate Cancer Patients","volume":"21","author":"Xu","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2025.102935_b0225","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1200\/JCO.2007.11.4769","article-title":"Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer","volume":"25","author":"Armstrong","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102935_b0230","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1200\/JCO.2013.50.3201","article-title":"Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy","volume":"31","author":"Halabi","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102935_b0235","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1200\/JCO.23.01535","article-title":"Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer","volume":"42","author":"Halabi","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102935_b0240","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s00228-019-02736-8","article-title":"Evaluation of potential surrogate endpoints for prediction of overall survival in patients with castration-resistant prostate cancer: trial-level meta-analysis","volume":"75","author":"Chen","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ctrv.2025.102935_b0245","doi-asserted-by":"crossref","first-page":"6139","DOI":"10.1200\/JCO.2005.08.156","article-title":"Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer?","volume":"23","author":"Collette","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102935_b0250","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.clgc.2021.11.007","volume":"20","author":"Woo","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ctrv.2025.102935_b0255","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.clgc.2016.03.022","article-title":"Trial Level Analysis of Prostate-Specific Antigen-Related Versus Unrelated Endpoints in Phase III Trials of First-Line and Second-Line Medical Treatments of Patients With Metastatic Castration-Resistant Prostate Cancer","volume":"14","author":"Colloca","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ctrv.2025.102935_b0055","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv156","article-title":"Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors","volume":"107","author":"Chen","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2025.102935_b0275","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2014.55.3875","article-title":"Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results","volume":"33","author":"Morris","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102935_b0280","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1001\/jamaoncol.2017.5808","article-title":"Radiographic progression-free survival as a clinically meaningful end point in metastatic Castration-resistant prostate cancer: the PREVAIL randomized clinical Trial","volume":"4","author":"Rathkopf","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2025.102935_b0060","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1158\/2326-6066.CIR-17-0465","article-title":"Designing Late-Stage Randomized Clinical Trials with Cancer Immunotherapy: Can We Make It Simpler?","volume":"6","author":"Chen","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ctrv.2025.102935_b0260","doi-asserted-by":"crossref","first-page":"4959","DOI":"10.1158\/1078-0432.CCR-16-3065","article-title":"Immuno-oncology trial endpoints: capturing clinically meaningful activity","volume":"23","author":"Anagnostou","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2025.102935_b0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104286","article-title":"Second-line treatment options in metastatic castration-resistant prostate cancer after progression on first-line androgen-receptor targeting therapies: A systematic review and Bayesian network analysis","volume":"196","author":"Xiong","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ctrv.2025.102935_b0270","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(21)00950-8","article-title":"Prostate cancer","volume":"398","author":"Sandhu","year":"2021","journal-title":"Lancet"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573722500057X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573722500057X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T21:27:08Z","timestamp":1762291628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030573722500057X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":55,"alternative-id":["S030573722500057X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.102935","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Operationalizing intermediate clinical endpoints: A pragmatic framework for prostate cancer management trials","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.102935","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102935"}}